Truist Financial’s Castle Biosciences CSTL Stock Holding History
Bought
Maintained
Sold
Other funds holding CSTL
Truist Financial's CSTL Position: Q3 2026 in Review
Truist Financial reduced its Castle Biosciences (CSTL) stake by 1.3% in Q3 2026, selling an estimated $9.7K and leaving 23,466 shares worth $834K. The position accounts for ﹤0.01% of the portfolio, ranked #1877.
Truist Financial first reported a position in CSTL in Q2 2021 and has held it in 18 quarters since. The position peaked at $919K in Q4 2025. 58 funds tracked by Wall St. Rank hold CSTL as of Q3 2026.
- Truist Financial held 23,466 shares of Castle Biosciences worth $834K as of Q3 2026.
- Truist Financial sold 320 Castle Biosciences shares in Q3 2026, an estimated $9.7K.
- Castle Biosciences made up ﹤0.01% of Truist Financial's portfolio in Q3 2026, its #1877 holding.
- Truist Financial first reported a position in Castle Biosciences in Q2 2021 and has held it in 18 quarters since.
- Truist Financial's Castle Biosciences position peaked at $919K in Q4 2025.
- 58 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2026.
Based on Truist Financial's 13F filing for Q3 2026, filed 30 Oct 2026.